• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Roivant Sciences Ltd. (Amendment)

    2/14/24 4:46:41 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ROIV alert in real time by email
    SC 13G/A 1 eps11181.htm
     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

     

    Roivant Sciences Ltd.
    (Name of Issuer)
    Common Shares
    (Title of Class of Securities)
    G76279 101
    (CUSIP Number)
    12/31/2023
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     1

    NAME OF REPORTING PERSON

    Vivek Ramaswamy

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP       (a) ☐    (b) ☒

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    U.S.

    NUMBER OF
    SHARES BENEFICIALLY OWNED
    BY EACH REPORTING PERSON
    WITH
    5

    SOLE VOTING POWER

    81,454,521 (1)

    6

    SHARED VOTING POWER

    -

    7

    SOLE DISPOSITIVE POWER

    81,454,521 (1)

    8

    SHARED DISPOSITIVE POWER

    -

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    81,454,521 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.75%

    12

    TYPE OF REPORTING PERSON

    IN

           

     

    (1) Consists of (i) 51,929,426 shares of restricted stock covering common shares that are fully vested (“RSAs”) and (ii) 29,525,095 common shares underlying stock options to purchase common shares (“Options”).

    (2) Percentage ownership is based on (i) 805,846,006 common shares issued and outstanding as of February 9, 2024 as disclosed by the Issuer in its Form 10-Q for the quarterly period ended December 31, 2023, as filed with the Securities and Exchange Commission on February 13, 2024 and (ii) 25,525,095 common shares underlying Options held by Mr. Ramaswamy that are subject to vesting and settlement within 60 days of December 31, 2023 and are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i).

     

     

     

     

    ITEM 1.(a) Name of Issuer:

    Roivant Sciences Ltd.

    (b)Address of Issuer’s Principal Executive Offices:

    7th Floor, 50 Broadway, London SW1H 0DB, United Kingdom.

    ITEM 2.(a) Name of Person Filing:

    This Amendment to Schedule 13G (the “Amendment”) is being filed by Vivek Ramaswamy (the “Reporting Person”).

    (b)Address of Principal Business Office, or if None, Residence:

    PO BOX 20860
    COLUMBUS, OH 43220.

    (c)Citizenship or Place of Organization:

    See row 4 of the cover page to this Amendment.

    (d)Title of Class of Securities:

    Common Shares, $0.0000000341740141 per share.

    (e)CUSIP Number: G76279 101
    ITEM 3.IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

    Not Applicable.

    ITEM 4.OWNERSHIP.

    All calculations of percentage ownership herein are based on an aggregate of 835,371,101 common shares issued and outstanding as of February 9, 2024, based on (i) 805,846,006 common shares issued and outstanding as of February 9, 2024 as disclosed by the Issuer in its Form 10-Q for the quarterly period ended December 31, 2023, as filed with the Securities and Exchange Commission on February 13, 2024 and (ii) 29,525,095 common shares underlying Options held by Mr. Ramaswamy that are subject to vesting and settlement within 60 days of December 31, 2023 and are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i).

    The information set forth in Item 2 above is incorporated by reference for the Reporting Person.

    (a)Amount beneficially owned:

     

    81,454,521 common shares, consisting of (i) 51,929,426 RSAs covering common shares and (ii) 29,525,095 common shares underlying Options.

    (b)Percent of class:

     

    9.75%

     

     

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote:

     

    81,454,521 common shares, consisting of (i) 51,929,426 RSAs covering common shares and (ii) 29,525,095 common shares underlying Options.

     

    (ii)Shared power to vote or to direct the vote:

     

    N/A

    (iii)Sole power to dispose or to direct the disposition of:

     

    81,454,521 common shares, consisting of (i) 51,929,426 RSAs covering common shares and (ii) 29,525,095 common shares underlying Options.

    (iv)Shared power to dispose or to direct the disposition of:

     

    N/A

    ITEM 5.OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

    Not Applicable.

    ITEM 6.OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

    Not Applicable.

    ITEM 7.IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

    Not Applicable.

    ITEM 8.IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

    Not Applicable.

    ITEM 9.NOTICE OF DISSOLUTION OF GROUP.

    Not Applicable.

    ITEM 10.CERTIFICATIONS.

    Not Applicable.

     

     

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 13, 2024

     

     

    By:  /s/ Vivek Ramaswamy      

    Name: Vivek Ramaswamy

     

     

    Get the next $ROIV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ROIV

    DatePrice TargetRatingAnalyst
    3/20/2026$35.00Outperform
    Bernstein
    9/2/2025$16.00Buy
    Citigroup
    7/10/2025$19.00Buy
    Goldman
    2/15/2024$17.00Outperform
    Wolfe Research
    1/5/2024$20.00Overweight
    Piper Sandler
    12/12/2023$14.00Buy
    Deutsche Bank
    10/17/2023$17.00Buy
    Guggenheim
    6/8/2023$10.50Neutral
    BofA Securities
    More analyst ratings

    $ROIV
    SEC Filings

    View All

    SEC Form 144 filed by Roivant Sciences Ltd.

    144 - Roivant Sciences Ltd. (0001635088) (Subject)

    3/17/26 4:17:54 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.

    SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    3/6/26 10:05:20 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant Sciences Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Roivant Sciences Ltd. (0001635088) (Filer)

    3/3/26 4:15:36 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ROIV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ROIV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ROIV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ROIV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

    Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industrySettlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the caseGenevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Geneva

    3/3/26 4:15:00 PM ET
    $ABUS
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

    Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industrySettlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the caseGenevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Geneva

    3/3/26 4:15:00 PM ET
    $ABUS
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis

    FDA assigns PDUFA target action date in the third quarter of calendar year 2026 with launch expected at the end of September 2026Priority Review supported by positive Phase 3 VALOR results, the first positive 52-week placebo-controlled trial in dermatomyositisIf approved, brepocitinib would represent the first targeted therapy approved for dermatomyositis DURHAM, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for brepocitinib for the treatment of dermatomyositis (DM) and has granted the application Priority Review. The FDA has assigned a Prescription Drug User Fee

    3/3/26 7:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Venker Eric

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    3/19/26 6:36:44 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Epperly Melissa B,

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    3/18/26 6:23:29 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Pulik Richard covered exercise/tax liability with 1,000 shares, decreasing direct ownership by 0.42% to 238,413 units (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    2/24/26 6:43:53 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernstein initiated coverage on Roivant Sciences with a new price target

    Bernstein initiated coverage of Roivant Sciences with a rating of Outperform and set a new price target of $35.00

    3/20/26 8:36:50 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Roivant Sciences with a new price target

    Citigroup initiated coverage of Roivant Sciences with a rating of Buy and set a new price target of $16.00

    9/2/25 8:40:38 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Roivant Sciences with a new price target

    Goldman resumed coverage of Roivant Sciences with a rating of Buy and set a new price target of $19.00

    7/10/25 9:00:08 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Gline Matthew bought $49,957 worth of shares (3,315 units at $15.07), increasing direct ownership by 0.02% to 17,287,081 units (SEC Form 4)

    4 - Roivant Sciences Ltd. (0001635088) (Issuer)

    9/18/25 7:28:11 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ROIV
    Financials

    Live finance-specific insights

    View All

    Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

    Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industrySettlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the caseGenevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Geneva

    3/3/26 4:15:00 PM ET
    $ABUS
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

    Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appealIf the $1.3 billion payment is realized, this settlement will be the largest disclosed patent settlement paid in the pharmaceutical industry and the second largest in any industrySettlement holds Moderna accountable for infringement and provides for the court to enter judgment of no invalidity on the four Genevant/Arbutus patents asserted in the caseGenevant grants Moderna a global non-exclusive license to its LNP delivery technology for SM-102-containing mRNA vaccines for infectious disease and a covenant not to sue for certain Geneva

    3/3/26 4:15:00 PM ET
    $ABUS
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

    Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 P<0.0001). Brepocitinib demonstrated rapid, deep and sustained improvements across all other efficacy endpoints measured with consistent safety profilePriovant plans to progress CS to a pivotal program with a Phase 3 study starting in calendar year 2026 following engagement with the FDA, representing the third indication with a pivotal program for brepocitinib New Drug Application (NDA) was submitted to the FDA for brepocitinib in dermatomyositis (DM). Topline data from Phase 3 studies in non-infectiou

    2/6/26 7:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ROIV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

    SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    11/14/24 4:31:06 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Roivant Sciences Ltd.

    SC 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)

    11/12/24 4:58:58 PM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Roivant Sciences Ltd.

    SC 13G - Roivant Sciences Ltd. (0001635088) (Subject)

    11/12/24 10:34:18 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ROIV
    Leadership Updates

    Live Leadership Updates

    View All

    Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600

    NEW YORK, March 26, 2024 /PRNewswire/ -- Roivant Sciences Ltd (NASD:ROIV) will replace Sunrun Inc. (NASD:RUN) in the S&P MidCap 400, and Sunrun will replace PGT Innovations Inc. (NYSE:PGTI) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, April 1. MITER Brands is acquiring PGT Innovations in a transaction expected to be completed on or about March 28 pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector April 1, 2024 S&P MidCap 400 Addition Roivant Sciences ROIV Health Care S&P MidCap 400 Deletion Sunrun RUN In

    3/26/24 6:22:00 PM ET
    $PGTI
    $ROIV
    $RUN
    Building Products
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors

    BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced the appointment of Mayukh Sukhatme, M.D., to its Board of Directors, effective immediately. Dr. Sukhatme will fill a newly created Class III seat on the Board of Directors, increasing the Board of Directors to eight members in total. "I'm thrilled to be adding Mayukh to our board. Mayukh has been with the company since almost the very beginning, and his contributions are too many to enumerate here. He has helped find and guide all of our key pipeline programs, and I am confident that his voice on our board will continue to further our important work for patients. It continue

    11/10/23 8:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer

      BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, is pleased to announce the appointment of Vincent Hennemand as Chief Executive Officer (CEO). Vincent Hennemand is a seasoned executive with a distinguished career in the pharmaceutical and biotechnology industry. With an exceptional track record of leadership, a passion for advancing healthcare, novel classes of therapeutics, and in-depth experience in immunology therapies, Vincent is poised to guide Covant Therapeutics into a new era of growth, innovation, and patient-centric excellence. Vincent joins Covant Therapeutics from his previous role as COO at Intergalactic T

    10/13/23 8:00:00 AM ET
    $ROIV
    Biotechnology: Pharmaceutical Preparations
    Health Care